Funded Tech Companies
IgGenix
IgGenix, operating out of San Francisco, received equity investments from Eli Lilly and Company, Alexandria Venture Investments and Khosla Ventures.
Company Overview
Company Name
IgGenix
Company Status
Private & Independent
Industry
Funding Rounds
Total Funding
Contact Information
Mailing Address
329 Oyster Point Blvd. 3rd Floor
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Company Background Information
Overview
IgGenix is a privately-held biotechnology company taking a revolutionary approach to directly address food and other severe allergies by re-engineering key antibodies involved in the allergic cascade. IgGenix isolates and transforms allergen-specific IgE antibodies into IgG antibodies that are designed to alleviate and possibly prevent the allergic cascade.
Profile
Social Media
Company News
Facebook
YouTube
Last Transaction
2/7/2023
Financing History
Date
Type
Amount
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jessica Grossman
Chief Scientific Officer
Richard Boismenu
Chief Technical Officer
Derek Croote
Company Investors
- Eli Lilly and Company
- Alexandria Venture Investments (Joel Marcus)
- Khosla Ventures
- AllerFund
- Private Investors (Sean Parker)
- Shangbay Capital
- Private Investors (Matthias Westman)
- Parker Price Venture Capital
Browse more funded tech companies:
Share this article
About Our Venture Capital Database
This venture capital transaction data comes via a partnership with VentureDeal.com, a leading provider of venture capital transaction data.
Additional Resources for Entrepreneurs